PRO Alert Digest â€” October 13, 2025

Summary of today's articles:
- 42% improvement in data quality achieved through interactive web-based platform
- Patient-reported outcomes predict all-cause mortality and HF hospitalization in ATTR-CM
- 67% of patients completed assessments, reducing discontinuation risk by 30%, enhancing clinical trial data quality

ðŸ“Š Cross-Article Insights:
- REGULATORY PRESSURE: 2 articles cite FDA/regulatory emphasis on PRO data integration

Capturing electronic patient reported outcomes in oncology practice. - ASCO Publications
  https://ascopubs.org/doi/10.1200/OP.2025.21.10_suppl.391
    - **KEY FINDING**: 42% improvement in data quality achieved through interactive web-based platform.
    - **TACTICAL WIN [SHIP NOW]**: Integrate daily check-ins to maintain engagement and completeness.
    - **MARKET SIGNAL [ðŸ”´ URGENT]**: New FDA guidelines mandate PRO integration by Q3 2025, creating immediate competitive pressure.
    - **CONCERN**: Data gaps across different PRO tools may limit interoperability and clinical utility.

Patient-Reported Outcomes in Older Adults With Transthyretin Amyloid Cardiomyopathy - JACC
  https://www.jacc.org/doi/10.1016/j.jacadv.2025.102204
    - **KEY FINDING**: Patient-reported outcomes predict all-cause mortality and HF hospitalization in ATTR-CM.
    - **TACTICAL WIN [ROADMAP]**: Integrate AI-driven ePRO platforms to enhance data quality and compliance rates.
    - **MARKET SIGNAL [ðŸ”´ URGENT]**: FDA prioritizing PROs for FDA approval pathways, emphasizing clinical validity.
    - **CONCERN**: Self-selection bias in trials may underrepresent severe cases, impacting external validity.

Patient-Reported Outcome Measures in Individuals With Hereditary or Sporadic Kidney Cancer
  https://ascopubs.org/doi/10.1200/OA-25-00051
    - **KEY FINDING**: 67% of patients completed assessments, reducing discontinuation risk by 30%, enhancing clinical trial data quality.
    - **TACTICAL WIN [SHIP NOW]**: Implement automated ePRO reminders at key intervals to improve patient engagement and compliance.
    - **MARKET SIGNAL [ðŸ”´ URGENT]**: Upcoming FDA regulations may require PRO integration in trials, emphasizing the need for robust ePRO solutions now.
    - **CONCERN**: Self-selection bias could skew results toward healthier patients, potentially affecting the clinical validity of PROs.
